# Alvopem® (Pemetrexed) Safety Assessment

> **NCT04843007** · — · COMPLETED · sponsor: **NanoAlvand** · enrollment: 199 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- Malignant Pleural Mesothelioma

## Interventions

- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT04843007
- **Lead sponsor:** NanoAlvand
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03-15
- **Primary completion:** 2020-01-22
- **Final completion:** 2020-01-22
- **Target enrollment:** 199 (ACTUAL)
- **Last updated:** 2024-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04843007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04843007, "Alvopem® (Pemetrexed) Safety Assessment". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04843007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*